Kian Eftekhari, MD
Ophthalmology · Salt Lake City, UTNPI 1689991747
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 80.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $194 and has fallen 68.2% since, to $62 in 2025. That places this record below the midpoint for ophthalmology clinicians in UT, where the typical reported total is $987.
Across 27 payments — averaging $25.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$560
- AbbVie$101
- Merz North America, Inc.$22
- Galderma Laboratories, L.p.$18
Across 3 payments — averaging $4209.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$13K
What the payments were for
- Food & beverage$67696%
- Education$254%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 20 | $560 |
| AbbVie(2 entities) | 5 | $101 |
| Merz North America, Inc. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$249
How this compares
$700 in reported general payments places this provider in the 40th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 118 | $1,592 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 30 | $368 |
| Methylprednisolone | 15 | $153 |
| Cephalexin | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.